1Adjei AA,Argiris A, Murren JR. Docelaxel and irinolecan, alone and in combination, in the treatment of non-small cell lung cancer [J]. Sere in Oncol, 1999,26(6):32-40.
2Bunn PA Jr, Kelley K. New chemotherapeutic agents prolong survival and improve quality of life in non - small cell lung cancer; a review of the literature and future directions[J]. Clin Cancer Res, 1998,4(5):1087-1100.
3Mukohara, Takeda. Japanese experience with second-line chemotherapy with low-dose (60 mg/m^2) docetaxel in patients with advanced non-small-cell lung cancer[J]. Cancer-Chemother-Pharmacol. 2001 Nov,48(5): 356-360.
4Perng RP,Shih JF,Chen YM,et al. A phase Ⅱ study of single agent docelaxel chemotherapy for non-small cell lung cancer[J]. Jpn J Clin Oncol, 2000,30(10) :429-434.
5Goh BC, Lehnerl M, Lin HL,et al. Phase Ⅱ trial of docelaxel in Asian patients with inoperable stage Ⅲ non-small cell lung cancer [J]. Asia Oncol,2000, 39(2) :225-229.
6Lynch,-T-J Jr. Review of two phase Ⅱ randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancer[J]. Semin-Oncol. 2001 Jun,28:5-9.
7Fossella FV, Devore R, Kerr RN, et al. Randomized phase Ⅲ trial of docelaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum- containing chemotherapy regimens [J]. J Clin Oncol,2000,18(12) :2354-2362.
8Hainsworth JD, Burris Ⅲ HA, Litchy S, et al. Weekly docelaxel in the treatment of elderly patients with advanced non- small cell lung carcinoma [J]. Cancer, 2000,89 ( 2 ), 328 -333.
9Hejna M, Kornek GV, Raderer M, et al. Treatment of patients with advanced non-small cell lung carcinoma using docelaxel and gemcitabine plus granulocyte-colony stimulating fator [J]. Cancer,2000,89(3) :516-522.
10Frassineti. Docetaxel followed by gemcitabine in the treatment of advanced non-small cell lung cancer:a phase I study[J].Tumori,2002 Mar-Apr,88(2) : 99-103.
